vs
Side-by-side financial comparison of C & F FINANCIAL CORP (CFFI) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
C & F FINANCIAL CORP is the larger business by last-quarter revenue ($35.9M vs $18.7M, roughly 1.9× CytomX Therapeutics, Inc.). C & F FINANCIAL CORP runs the higher net margin — 18.7% vs -0.8%, a 19.5% gap on every dollar of revenue. On growth, C & F FINANCIAL CORP posted the faster year-over-year revenue change (12.0% vs -25.7%). C & F FINANCIAL CORP produced more free cash flow last quarter ($22.2M vs $-15.8M). Over the past eight quarters, C & F FINANCIAL CORP's revenue compounded faster (8.2% CAGR vs -15.9%).
Sun Life Financial Inc. is a Canadian financial services company headquartered in Toronto, Ontario. Founded in 1865, it operates internationally in life insurance, wealth management, and asset management. As of 2024, the company manages over CAD$1.3 trillion in assets and serves clients in Canada, the United States, Asia, and other markets.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CFFI vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.9M | $18.7M |
| Net Profit | $6.7M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | 22.6% | -6.9% |
| Net Margin | 18.7% | -0.8% |
| Revenue YoY | 12.0% | -25.7% |
| Net Profit YoY | 11.0% | 97.6% |
| EPS (diluted) | $2.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.9M | — | ||
| Q3 25 | $36.0M | — | ||
| Q2 25 | $36.4M | $18.7M | ||
| Q1 25 | $32.6M | $50.9M | ||
| Q4 24 | $32.0M | $38.1M | ||
| Q3 24 | $33.5M | $33.4M | ||
| Q2 24 | $31.2M | $25.1M | ||
| Q1 24 | $30.6M | $41.5M |
| Q4 25 | $6.7M | — | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $7.7M | $-154.0K | ||
| Q1 25 | $5.4M | $23.5M | ||
| Q4 24 | $6.0M | $18.9M | ||
| Q3 24 | $5.4M | $5.7M | ||
| Q2 24 | $5.0M | $-6.5M | ||
| Q1 24 | $3.4M | $13.8M |
| Q4 25 | 22.6% | — | ||
| Q3 25 | 24.5% | — | ||
| Q2 25 | 26.5% | -6.9% | ||
| Q1 25 | 20.0% | 44.4% | ||
| Q4 24 | 22.6% | 46.4% | ||
| Q3 24 | 19.9% | 12.3% | ||
| Q2 24 | 20.0% | -33.7% | ||
| Q1 24 | 13.1% | 28.1% |
| Q4 25 | 18.7% | — | ||
| Q3 25 | 19.6% | — | ||
| Q2 25 | 21.2% | -0.8% | ||
| Q1 25 | 16.5% | 46.2% | ||
| Q4 24 | 18.8% | 49.6% | ||
| Q3 24 | 16.1% | 17.2% | ||
| Q2 24 | 16.1% | -26.0% | ||
| Q1 24 | 11.1% | 33.3% |
| Q4 25 | $2.08 | — | ||
| Q3 25 | $2.18 | — | ||
| Q2 25 | $2.37 | — | ||
| Q1 25 | $1.66 | — | ||
| Q4 24 | $1.85 | — | ||
| Q3 24 | $1.65 | — | ||
| Q2 24 | $1.50 | — | ||
| Q1 24 | $1.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $261.8M | $119.9M |
| Total Assets | $2.8B | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | — | $43.2M | ||
| Q1 24 | — | $36.2M |
| Q4 25 | $261.8M | — | ||
| Q3 25 | $253.3M | — | ||
| Q2 25 | $240.3M | $119.9M | ||
| Q1 25 | $234.6M | $25.0M | ||
| Q4 24 | $226.4M | $-456.0K | ||
| Q3 24 | $227.3M | $-23.5M | ||
| Q2 24 | $218.5M | $-31.2M | ||
| Q1 24 | $216.3M | $-31.7M |
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.7B | $175.1M | ||
| Q1 25 | $2.6B | $98.5M | ||
| Q4 24 | $2.6B | $120.5M | ||
| Q3 24 | $2.6B | $139.0M | ||
| Q2 24 | $2.5B | $159.2M | ||
| Q1 24 | $2.5B | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $24.5M | $-15.8M |
| Free Cash FlowOCF − Capex | $22.2M | $-15.8M |
| FCF MarginFCF / Revenue | 61.8% | -84.6% |
| Capex IntensityCapex / Revenue | 6.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 3.65× | — |
| TTM Free Cash FlowTrailing 4 quarters | $42.8M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.5M | — | ||
| Q3 25 | $23.4M | — | ||
| Q2 25 | $-4.4M | $-15.8M | ||
| Q1 25 | $3.2M | $-21.0M | ||
| Q4 24 | $36.8M | $-19.9M | ||
| Q3 24 | $404.0K | $-20.7M | ||
| Q2 24 | $1.7M | $-19.5M | ||
| Q1 24 | $895.0K | $-26.0M |
| Q4 25 | $22.2M | — | ||
| Q3 25 | $22.7M | — | ||
| Q2 25 | $-5.0M | $-15.8M | ||
| Q1 25 | $2.9M | $-21.2M | ||
| Q4 24 | $33.3M | $-20.0M | ||
| Q3 24 | $-1.6M | $-20.7M | ||
| Q2 24 | $1.2M | $-19.6M | ||
| Q1 24 | $410.0K | $-26.2M |
| Q4 25 | 61.8% | — | ||
| Q3 25 | 63.0% | — | ||
| Q2 25 | -13.6% | -84.6% | ||
| Q1 25 | 9.0% | -41.6% | ||
| Q4 24 | 103.8% | -52.5% | ||
| Q3 24 | -4.9% | -62.1% | ||
| Q2 24 | 3.7% | -78.2% | ||
| Q1 24 | 1.3% | -63.1% |
| Q4 25 | 6.5% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 1.6% | 0.1% | ||
| Q1 25 | 0.8% | 0.2% | ||
| Q4 24 | 10.9% | 0.2% | ||
| Q3 24 | 6.1% | 0.1% | ||
| Q2 24 | 1.7% | 0.4% | ||
| Q1 24 | 1.6% | 0.3% |
| Q4 25 | 3.65× | — | ||
| Q3 25 | 3.31× | — | ||
| Q2 25 | -0.57× | — | ||
| Q1 25 | 0.60× | -0.89× | ||
| Q4 24 | 6.09× | -1.05× | ||
| Q3 24 | 0.07× | -3.61× | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.26× | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFFI
| Community Banking | $25.9M | 72% |
| Consumer Finance Segment | $7.0M | 19% |
| Mortgage Banking Segment | $1.9M | 5% |
| Other | $1.1M | 3% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
